

## Mélanie Caron

---

**De:** Kate Lee [REDACTED]  
**Envoyé:** 2 juin 2021 18:47  
**À:** Mélanie Caron  
**Cc:** [REDACTED]  
**Objet:** ACTION ITEMS - : Focus Group RE: biologics/biosimilars  
**Pièces jointes:** IBD considerations Jun 2 2021.pdf

**Avertissement automatisé :** Ce courriel provient de l'extérieur de votre organisation. Ne cliquez pas sur les liens et les pièces jointes si vous ne reconnaissez pas l'expéditeur.

Good evening Mélanie,


First, I wanted to thank you again for our call today to discuss Quebec's biologics to biosimilars switch policy.

I am emailing with a couple of immediate action items we had discussed:

1. Attached is the presentation we shared with you today;
2. Copied on this email is Lori's Executive Assistant – Helen – who can work with you to identify a time for our next call in 3 weeks.

We look forward to learning more about the policy during our next call and working together to ensure a seamless switch.

Sincerely,  
Kate



**Kate Lee, PhD, MBA**  
Vice President, Research and Patient Programs  
**Crohn's and Colitis Canada**  
600 - 60 St. Clair Ave. E., Toronto ON M4T 1N5  
T: 416-920-5035 x 214  
Get Gutsy: [Learn](#) | [Volunteer](#) | [Donate](#)



**Together as one**

we walk to stop Crohn's and colitis.

Join our community on Sunday, June 6, 2021.  
Sign up at [gutsywalk.ca](https://gutsywalk.ca)